This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.


Short-term goals:

  • Deliver a Joint Working Agreement for the Partnership.
  • Support development, delivery and coordination of strategic plans across the Partners.
  • Create an integrated Oxford Joint Research Office across all OAHP partners to promote operational collaboration.
  • Establish a national network of Academic Health Science Centres (AHSCs) and Health Innovation Networks to support the Accelerated Access Collaborative (AAC) in demand signalling and horizon scanning for innovations and transformative technologies.

Medium-term goals:

  • Establish new early-stage clinical research facilities including cell and gene therapy operating at GMP, GLP and GCP standards.
  • Develop joint working and strategic planning with local authorities, residents and patient groups to coordinate new capital and infrastructure plans across the Oxford city-wide campus.
  • Develop the workforce in transformative technologies through education and training, in areas including big data, genomics, bioinformatics and advanced therapeutics.
  • Create a Centre for Healthcare Implementation & Change to train the workforce in approaches to implementation and adoption of innovation in the health system supporting local, regional and national programmes.
  • Extend partnerships with the Health Innovation Oxford and Thames Valley, NIHR Oxford and Thames Valley Applied Research Collaboration, ARC, Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board (BOB ICS) and the Health Innovation network providing academic support to evaluate innovations e.g. AAC rapid uptake products and facilitate adoption and spread.

Long-term goals:

  • Support the development of the OAHP partners’ estate, including a new clinical-academic campus dedicated to neuroscience and mental health, combining translational research with high-quality clinical care.
  • Expand capacity in target discovery for new drugs, building on public-private partnerships, and development of gene/nucleic acid therapies, including manufacturing capacity.
  • Develop the OAHP partners’ campus as an international centre for multi-disciplinary and cross-sector research, attracting major pharma and medtech companies to invest in Oxford to support the development of technologies and therapeutics to address national and international priorities.

The OAHP partners maintain a well-developed and linked health sciences campus, as shown below. It’s physical proximity will support the delivery of the above goals.